<p>First Turn Management LLC 在第二季度減持 Mirum Pharmaceuticals, Inc.（NASDAQ:MIRM - Free Report）股份，根據該公司最新提交給證券交易委員會的第 13F 表格，持股比例下降了 26.6%。該公司在此期間賣出了 255,256 股，持有 703,398 股公司股票。Mirum Pharmaceuticals 佔 First Turn Management LLC 投資組合的 3.9%，是其第 5 大持倉。根據最新提交給證券交易委員會的文件，First Turn Management LLC 持有的 Mirum Pharmaceuticals 價值約為$24,049,000。</p>
<p>獲取 <strong>Mirum Pharmaceuticals</strong> 警報：</p>
<p>一些其他對沖基金和其他機構投資者最近也增加或減少了他們對 MIRM 的持股。Quest Partners LLC 在第二季度將其對 Mirum Pharmaceuticals 的持股增加了 7,513.3%。Quest Partners LLC 現在擁有 1,142 股公司股票，價值$39,000，上季度購入了 1,127 股。StepStone Group LP 在第四季度購入了 Mirum Pharmaceuticals 的新股份，價值約為$135,000。NEOS Investment Management LLC 在第四季度購入了 Mirum Pharmaceuticals 的新股份，價值約為$220,000。中國通用資產管理有限公司在第一季度將其對 Mirum Pharmaceuticals 的持股增加了 66.0%。中國通用資產管理有限公司現在擁有 8,952 股公司股票，價值$225,000，上季度購入了 3,558 股。最後，亞利桑那州退休系統在第二季度將其對 Mirum Pharmaceuticals 的持股增加了 10.6%。亞利桑那州退休系統現在擁有 9,210 股公司股票，價值$315,000，上季度購入了 883 股。</p>
<h2>內部人士的買賣行為</h2>
<p>在其他 Mirum Pharmaceuticals 的消息中，內部人士 Pamela Vig 在 6 月 24 日星期一進行了一筆交易，賣出了 30,559 股公司股票。這些股票的平均價格為$34.00，總價值為$1,039,006.00。交易完成後，該內部人士直接持有公司股票 27,406 股，價值約為$931,804。該交易已在提交給 SEC 的文件中披露，可以通過此鏈接查看。公司股份的 22.87% 歸公司內部人士所有。</p>
<h2>Mirum Pharmaceuticals 股票表現</h2>
<p>MIRM 股票週五開盤價為$41.13。Mirum Pharmaceuticals, Inc.的 52 周最低價為$23.14，52 周最高價為$45.23。公司的流動比率為 3.28，速動比率為 3.09，負債權益比為 1.34。公司的五十天簡單移動平均為$40.46，兩百天簡單移動平均為$31.57。</p>
<p>Mirum Pharmaceuticals（NASDAQ:MIRM - Get Free Report）最近發佈了其季度收益報告，日期為 8 月 7 日星期三。公司報告季度每股虧損 ($0.52)，低於分析師預期的 ($0.47)。Mirum Pharmaceuticals 的淨資產收益率為-43.47%，淨利潤率為-40.34%。該季度公司收入為$77.90 百萬，超過分析師預期的$75.03 百萬。與去年同期相比，Mirum Pharmaceuticals 的季度收入增長了 107.7%。研究分析師預測，Mirum Pharmaceuticals, Inc.本財年的每股收益將達到-1.75 美元。</p>
<h2>華爾街分析師預測增長</h2>
<p>一些券商最近發佈了關於 MIRM 的報告。JMP Securities 將 Mirum Pharmaceuticals 的目標股價從$66.00 上調至$68.00，並在 6 月 18 日星期二的研究報告中給予該股 “市場表現優異” 評級。Evercore ISI 將 Mirum Pharmaceuticals 的目標股價從$62.00 上調至$66.00，並在 8 月 8 日星期四的研究報告中給予該股 “表現優異” 評級。摩根大通將 Mirum Pharmaceuticals 的目標股價從$31.00 上調至$39.00，並在 6 月 18 日星期二的研究報告中給予該股 “超配” 評級。花旗將 Mirum Pharmaceuticals 的目標股價從$38.00 上調至$64.00，並在 6 月 18 日星期二的研究報告中給予該股 “買入” 評級。最後，摩根士丹利將 Mirum Pharmaceuticals 的目標股價從$53.00 上調至$57.00，並在 6 月 18 日星期二的研究報告中給予該股 “超配” 評級。十位研究分析師對該股給予買入評級，兩位分析師給予強烈買入評級。根據 MarketBeat，Mirum Pharmaceuticals 的平均評級為 “買入”，目標股價一致預期為$56.27。</p>
<p><strong>查看我們關於 Mirum Pharmaceuticals 的最新股票報告</strong></p>
<h2>關於 Mirum Pharmaceuticals（免費報告）</h2>
<p>Mirum Pharmaceuticals, Inc.是一家生物製藥公司，專注於開發和商業化用於治療罕見和孤兒疾病的新型療法。其主要產品候選藥物是 LIVMARLI（maralixibat），一種口服和吸收極少的迴腸膽酸轉運蛋白（IBAT）抑制劑，已獲批用於治療美國和國際 Alagille 綜合徵患者的膽汁瘙癢症。</p>
<h2>精選文章</h2>
<ul>
<li>我們喜歡的五隻股票勝過 Mirum Pharmaceuticals</li>
<li>什麼是股息冠軍？如何投資冠軍</li>
<li>3 只槓桿 ETF，倍增回報</li>
<li>內幕交易 - 你需要了解的</li>
<li>兩位巨頭的故事：揭示百度和京東的價值</li>
<li>投資者如何識別併成功交易跳空股</li>
<li>AI 能力 iPhone 16 是銷售超級週期的開始嗎？</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9TUlSTQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9TUlSTQ"/></p>
<p><em>這則即時新聞警報是由敍事科技和來自 MarketBeat 的金融數據生成，旨在為讀者提供最快速和準確的報道。在發佈之前，該故事已經經過 MarketBeat 的編輯團隊審查。請將有關此故事的任何問題或評論發送至 contact@marketbeat.com。</em></p>
<p>→ 你絕對不會相信這位前華爾街內部人士在選舉中發現了什麼（來自 Banyan Hill Publishing）（廣告）</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD05NTc1?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD05NTc1"/></p>
<h2>現在是否值得投資$1,000 在 Mirum Pharmaceuticals？</h2>
<p>在考慮 Mirum Pharmaceuticals 之前，您應該聽聽這個。</p>
<p>MarketBeat 追蹤華爾街評級最高且表現最佳的研究分析師以及他們每天向客户推薦的股票。MarketBeat 已經確定了五隻頂級分析師悄悄告訴他們的客户現在購買的股票，然後再更廣泛市場注意到之前...而 Mirum Pharmaceuticals 並不在名單上。</p>
<p>雖然 Mirum Pharmaceuticals 目前在分析師中有一個 “買入” 評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>查看這五隻股票</p>

MIRM

<p>First Turn Management LLC 在第二季度將其在 Mirum Pharmaceuticals, Inc.（NASDAQ：MIRM）的持股比例減少了 26.6％，現持有 703,398 股。該公司持有的 Mirum 股份佔其投資組合的 3.9％。其他投資者，包括 Quest Partners LLC 和亞利桑那州退休系統，也調整了他們的持股比例。Mirum 的股價開盤為 22.13 美元，52 周股價範圍為 14.14 美元至 23.23 美元。該公司報告了年同比增長 107.7％的營收，但未達到每股收益預期。分析師普遍對該股票給予了積極評價，最近有幾家機構提高了價格目標</p>

<p>First Turn Management LLC decreased its stake in shares of Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM - Free Report) by 26.6% during the second quarter, according to the company in its most recent Form 13F filing with the Securities &amp; Exchange Commission. The firm owned 703,398 shares of the company's stock after selling 255,256 shares during the period. Mirum Pharmaceuticals comprises 3.9% of First Turn Management LLC's portfolio, making the stock its 5th largest holding. First Turn Management LLC owned about 1.49% of Mirum Pharmaceuticals worth $24,049,000 as of its most recent filing with the Securities &amp; Exchange Commission.</p>
<div class="lb-trans"><p>First Turn Management LLC 在第二季度減持 Mirum Pharmaceuticals, Inc.（NASDAQ:MIRM - Free Report）股份，根據該公司最新提交給證券交易委員會的第 13F 表格，持股比例下降了 26.6%。該公司在此期間賣出了 255,256 股，持有 703,398 股公司股票。Mirum Pharmaceuticals 佔 First Turn Management LLC 投資組合的 3.9%，是其第 5 大持倉。根據最新提交給證券交易委員會的文件，First Turn Management LLC 持有的 Mirum Pharmaceuticals 價值約為$24,049,000。</p>
</div><p>Get <strong>Mirum Pharmaceuticals</strong> alerts:</p>
<div class="lb-trans"><p>獲取 <strong>Mirum Pharmaceuticals</strong> 警報：</p>
</div><p>A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in MIRM. Quest Partners LLC increased its holdings in Mirum Pharmaceuticals by 7,513.3% during the second quarter. Quest Partners LLC now owns 1,142 shares of the company's stock valued at $39,000 after buying an additional 1,127 shares during the last quarter. StepStone Group LP purchased a new stake in Mirum Pharmaceuticals during the fourth quarter valued at approximately $135,000. NEOS Investment Management LLC purchased a new stake in Mirum Pharmaceuticals during the fourth quarter valued at approximately $220,000. China Universal Asset Management Co. Ltd. increased its stake in shares of Mirum Pharmaceuticals by 66.0% in the first quarter. China Universal Asset Management Co. Ltd. now owns 8,952 shares of the company's stock worth $225,000 after purchasing an additional 3,558 shares in the last quarter. Finally, Arizona State Retirement System increased its stake in shares of Mirum Pharmaceuticals by 10.6% in the second quarter. Arizona State Retirement System now owns 9,210 shares of the company's stock worth $315,000 after purchasing an additional 883 shares in the last quarter.</p>
<div class="lb-trans"><p>一些其他對沖基金和其他機構投資者最近也增加或減少了他們對 MIRM 的持股。Quest Partners LLC 在第二季度將其對 Mirum Pharmaceuticals 的持股增加了 7,513.3%。Quest Partners LLC 現在擁有 1,142 股公司股票，價值$39,000，上季度購入了 1,127 股。StepStone Group LP 在第四季度購入了 Mirum Pharmaceuticals 的新股份，價值約為$135,000。NEOS Investment Management LLC 在第四季度購入了 Mirum Pharmaceuticals 的新股份，價值約為$220,000。中國通用資產管理有限公司在第一季度將其對 Mirum Pharmaceuticals 的持股增加了 66.0%。中國通用資產管理有限公司現在擁有 8,952 股公司股票，價值$225,000，上季度購入了 3,558 股。最後，亞利桑那州退休系統在第二季度將其對 Mirum Pharmaceuticals 的持股增加了 10.6%。亞利桑那州退休系統現在擁有 9,210 股公司股票，價值$315,000，上季度購入了 883 股。</p>
</div><h2>Insider Buying and Selling</h2>
<div class="lb-trans"><h2>內部人士的買賣行為</h2>
</div><p>In other Mirum Pharmaceuticals news, insider Pamela Vig sold 30,559 shares of the business's stock in a transaction dated Monday, June 24th. The shares were sold at an average price of $34.00, for a total value of $1,039,006.00. Following the completion of the sale, the insider now directly owns 27,406 shares of the company's stock, valued at approximately $931,804. The transaction was disclosed in a filing with the SEC, which is available through this link. 22.87% of the stock is owned by corporate insiders.</p>
<div class="lb-trans"><p>在其他 Mirum Pharmaceuticals 的消息中，內部人士 Pamela Vig 在 6 月 24 日星期一進行了一筆交易，賣出了 30,559 股公司股票。這些股票的平均價格為$34.00，總價值為$1,039,006.00。交易完成後，該內部人士直接持有公司股票 27,406 股，價值約為$931,804。該交易已在提交給 SEC 的文件中披露，可以通過此鏈接查看。公司股份的 22.87% 歸公司內部人士所有。</p>
</div><h2>Mirum Pharmaceuticals Stock Performance</h2>
<div class="lb-trans"><h2>Mirum Pharmaceuticals 股票表現</h2>
</div><p>MIRM stock opened at $41.13 on Friday. Mirum Pharmaceuticals, Inc. has a 52 week low of $23.14 and a 52 week high of $45.23. The company has a current ratio of 3.28, a quick ratio of 3.09 and a debt-to-equity ratio of 1.34. The company has a fifty day simple moving average of $40.46 and a two-hundred day simple moving average of $31.57.</p>
<div class="lb-trans"><p>MIRM 股票週五開盤價為$41.13。Mirum Pharmaceuticals, Inc.的 52 周最低價為$23.14，52 周最高價為$45.23。公司的流動比率為 3.28，速動比率為 3.09，負債權益比為 1.34。公司的五十天簡單移動平均為$40.46，兩百天簡單移動平均為$31.57。</p>
</div><p>Mirum Pharmaceuticals (NASDAQ:MIRM - Get Free Report) last released its quarterly earnings results on Wednesday, August 7th. The company reported ($0.52) EPS for the quarter, missing analysts' consensus estimates of ($0.47) by ($0.05). Mirum Pharmaceuticals had a negative return on equity of 43.47% and a negative net margin of 40.34%. The firm had revenue of $77.90 million for the quarter, compared to analysts' expectations of $75.03 million. During the same period in the prior year, the firm posted ($0.92) earnings per share. Mirum Pharmaceuticals's revenue for the quarter was up 107.7% on a year-over-year basis. Research analysts predict that Mirum Pharmaceuticals, Inc. will post -1.75 EPS for the current fiscal year.</p>
<div class="lb-trans"><p>Mirum Pharmaceuticals（NASDAQ:MIRM - Get Free Report）最近發佈了其季度收益報告，日期為 8 月 7 日星期三。公司報告季度每股虧損 ($0.52)，低於分析師預期的 ($0.47)。Mirum Pharmaceuticals 的淨資產收益率為-43.47%，淨利潤率為-40.34%。該季度公司收入為$77.90 百萬，超過分析師預期的$75.03 百萬。與去年同期相比，Mirum Pharmaceuticals 的季度收入增長了 107.7%。研究分析師預測，Mirum Pharmaceuticals, Inc.本財年的每股收益將達到-1.75 美元。</p>
</div><h2>Wall Street Analysts Forecast Growth</h2>
<div class="lb-trans"><h2>華爾街分析師預測增長</h2>
</div><p>A number of brokerages have recently issued reports on MIRM. JMP Securities increased their price objective on shares of Mirum Pharmaceuticals from $66.00 to $68.00 and gave the stock a &#34;market outperform&#34; rating in a research note on Tuesday, June 18th. Evercore ISI increased their price objective on shares of Mirum Pharmaceuticals from $62.00 to $66.00 and gave the stock an &#34;outperform&#34; rating in a research note on Thursday, August 8th. JPMorgan Chase &amp; Co. increased their price objective on shares of Mirum Pharmaceuticals from $31.00 to $39.00 and gave the stock an &#34;overweight&#34; rating in a research note on Tuesday, June 18th. Citigroup increased their price objective on shares of Mirum Pharmaceuticals from $38.00 to $64.00 and gave the stock a &#34;buy&#34; rating in a research note on Tuesday, June 18th. Finally, Morgan Stanley increased their price objective on shares of Mirum Pharmaceuticals from $53.00 to $57.00 and gave the stock an &#34;overweight&#34; rating in a research note on Tuesday, June 18th. Ten research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company. According to MarketBeat, Mirum Pharmaceuticals has an average rating of &#34;Buy&#34; and a consensus target price of $56.27.</p>
<div class="lb-trans"><p>一些券商最近發佈了關於 MIRM 的報告。JMP Securities 將 Mirum Pharmaceuticals 的目標股價從$66.00 上調至$68.00，並在 6 月 18 日星期二的研究報告中給予該股 “市場表現優異” 評級。Evercore ISI 將 Mirum Pharmaceuticals 的目標股價從$62.00 上調至$66.00，並在 8 月 8 日星期四的研究報告中給予該股 “表現優異” 評級。摩根大通將 Mirum Pharmaceuticals 的目標股價從$31.00 上調至$39.00，並在 6 月 18 日星期二的研究報告中給予該股 “超配” 評級。花旗將 Mirum Pharmaceuticals 的目標股價從$38.00 上調至$64.00，並在 6 月 18 日星期二的研究報告中給予該股 “買入” 評級。最後，摩根士丹利將 Mirum Pharmaceuticals 的目標股價從$53.00 上調至$57.00，並在 6 月 18 日星期二的研究報告中給予該股 “超配” 評級。十位研究分析師對該股給予買入評級，兩位分析師給予強烈買入評級。根據 MarketBeat，Mirum Pharmaceuticals 的平均評級為 “買入”，目標股價一致預期為$56.27。</p>
</div><p><strong>Check Out Our Latest Stock Report on Mirum Pharmaceuticals</strong></p>
<div class="lb-trans"><p><strong>查看我們關於 Mirum Pharmaceuticals 的最新股票報告</strong></p>
</div><h2>About Mirum Pharmaceuticals (Free Report)</h2>
<div class="lb-trans"><h2>關於 Mirum Pharmaceuticals（免費報告）</h2>
</div><p>Mirum Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally.</p>
<div class="lb-trans"><p>Mirum Pharmaceuticals, Inc.是一家生物製藥公司，專注於開發和商業化用於治療罕見和孤兒疾病的新型療法。其主要產品候選藥物是 LIVMARLI（maralixibat），一種口服和吸收極少的迴腸膽酸轉運蛋白（IBAT）抑制劑，已獲批用於治療美國和國際 Alagille 綜合徵患者的膽汁瘙癢症。</p>
</div><h2>Featured Articles</h2>
<ul>
<li>Five stocks we like better than Mirum Pharmaceuticals</li>
<li>What Are Dividend Champions? How to Invest in the Champions</li>
<li>3 Leveraged ETFs to Multiply Returns</li>
<li>Insider Trading - What You Need to Know</li>
<li>A Tale of Two Titans: Unveiling the Value in Baidu and JD.com</li>
<li>How Investors Can Identify and Successfully Trade Gap-Down Stocks</li>
<li>Is the AI-Capable iPhone 16 the Start of a Sales Super-Cycle?</li>
</ul>
<div class="lb-trans"><h2>精選文章</h2>
<ul>
<li>我們喜歡的五隻股票勝過 Mirum Pharmaceuticals</li>
<li>什麼是股息冠軍？如何投資冠軍</li>
<li>3 只槓桿 ETF，倍增回報</li>
<li>內幕交易 - 你需要了解的</li>
<li>兩位巨頭的故事：揭示百度和京東的價值</li>
<li>投資者如何識別併成功交易跳空股</li>
<li>AI 能力 iPhone 16 是銷售超級週期的開始嗎？</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9TUlSTQ" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NASDAQ&amp;Symbol=MIRM"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>這則即時新聞警報是由敍事科技和來自 MarketBeat 的金融數據生成，旨在為讀者提供最快速和準確的報道。在發佈之前，該故事已經經過 MarketBeat 的編輯團隊審查。請將有關此故事的任何問題或評論發送至 contact@marketbeat.com。</em></p>
</div><p>→ You won’t believe what this ex-Wall Street insider discovered about the election (From Banyan Hill Publishing)(Ad)</p>
<div class="lb-trans"><p>→ 你絕對不會相信這位前華爾街內部人士在選舉中發現了什麼（來自 Banyan Hill Publishing）（廣告）</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD05NTc1" alt="" original-src="https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx?TriggeredCampaignID=9575&amp;Placement=NativeDisplay&amp;Source=NativeDisplay"/></p>
<h2>Should you invest $1,000 in Mirum Pharmaceuticals right now?</h2>
<div class="lb-trans"><h2>現在是否值得投資$1,000 在 Mirum Pharmaceuticals？</h2>
</div><p>Before you consider Mirum Pharmaceuticals, you'll want to hear this.</p>
<div class="lb-trans"><p>在考慮 Mirum Pharmaceuticals 之前，您應該聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Mirum Pharmaceuticals wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 追蹤華爾街評級最高且表現最佳的研究分析師以及他們每天向客户推薦的股票。MarketBeat 已經確定了五隻頂級分析師悄悄告訴他們的客户現在購買的股票，然後再更廣泛市場注意到之前...而 Mirum Pharmaceuticals 並不在名單上。</p>
</div><p>While Mirum Pharmaceuticals currently has a &#34;Buy&#34; rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 Mirum Pharmaceuticals 目前在分析師中有一個 “買入” 評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>查看這五隻股票</p>
</div>

First Turn Management LLC 降低了其在 Mirum Pharmaceuticals, Inc.（納斯達克股票代碼：MIRM）的持倉